The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.

ABSTRACT:

Introduction

Upadacitinib is a Janus kinase inhibitor with demonstrated efficacy in patients with rheumatoid arthritis (RA).

Objective

The aim of this study was to assess the long-term safety of upadacitinib in patients with active RA from Japan compared with global clinical trial populations.

Methods

Pooled data in patients enrolled from Japan (the 'Japanese population'; SELECT-SUNRISE, SELECT-EARLY, and SELECT-MONOTHERAPY) were compared with that from global (Japan and ex-Japan) upadacitinib clinical trial populations and summarized descriptively.

Results

The Japanese population (mean age 57.0 years; mean RA duration 6.1 years) received upadacitinib 7.5 mg (n = 121), 15 mg (n = 126), and 30 mg (n = 124) once daily, while the global population (mean age 54.8 y

SUBMITTER: Yamaoka K 

PROVIDER: S-EPMC8184701 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature